LGND
NASDAQ
US
Ligand Pharmaceuticals Incorporated - Common Stock
$199.59
▼ $-0.03
(-0.02%)
Vol 222K
11
Quality Score
ok
Deep Check
1/5
fail
Rev ✗
NI ✓
>IPO ✗
Mkt Cap
$3.7B
P/E
76.6
ROE
5.7%
Margin
19.3%
D/E
46.89
Beta
1.52
52W
$94–$212
Wall Street Consensus
15 analysts · Apr 20266
Strong Buy
8
Buy
1
Hold
0
Sell
0
Strong Sell
93.3%
Buy Rating
Price Chart
Similar Stocks
AXSM
Axsome Therapeutics Inc
$9.2B
BLTE
Belite Bio Inc
$5.6B
TERN
Terns Pharmaceuticals Inc
$4.3B
CORT
Corcept Therapeutics Inc
P/E 34.5
$3.7B
AMRX
Amneal Pharmaceuticals Inc
P/E 671.4
$4.0B
CRNX
Crinetics Pharmaceuticals Inc
$4.4B
INDV
Indivior Pharmaceuticals, Inc
P/E 35.8
$4.5B
GPCR
Structure Therapeutics Inc
$4.2B
EWTX
Edgewise Therapeutics Inc
$2.6B
LQDA
Liquidia Corp
$3.0B
Earnings
Beat rate: 100.0%
Next Report
May 06, 2026
EPS Estimate: $2.02
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $2.02 | — | — |
| Dec 2025 | $1.59 | $2.02 | +$0.43 |
| Sep 2025 | $1.96 | $3.09 | +$1.13 |
| Jun 2025 | $1.45 | $1.60 | +$0.15 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -9.2% | -9.2% | -9.2% | -9.2% | 5.7% | 5.7% |
| P/E (TTM) | — | — | — | — | 79.04 | 76.60 |
| Net Margin | 10.2% | -40.4% | -40.4% | -40.4% | 19.3% | 19.3% |
| Gross Margin | 93.9% | 93.0% | 93.0% | 93.0% | 94.3% | 94.3% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 46.89 | 46.89 |
| Current Ratio | 5.45 | 5.45 | 5.45 | 5.45 | 24.69 | 24.69 |
Key Ratios
ROA (TTM)
4.6%
P/S (TTM)
14.81
P/B
2.4
EPS (TTM)
$2.08
CF/Share
$4.86
Rev Growth 3Y
-15.5%
52W High
$212.49
52W Low
$93.58
$93.58
52-Week Range
$212.49
How does LGND compare to Pharmaceuticals peers?
Peer group: Mid-cap Pharmaceuticals ($2B+) · 25 companies
LGND valuation vs Pharmaceuticals peers
P/E ratio
76.6
▲
150%
above
peers
(30.7)
vs Peers
vs Industry
Undervalued
P/S ratio
14.8
▲
120%
above
peers
(6.7)
vs Peers
vs Industry
Pricier
P/B ratio
2.4
▼
53%
below
peers
(5.2)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(3.1%)
vs Peers
vs Industry
Low yield
LGND profitability vs Pharmaceuticals peers
ROE
5.7%
▲
122%
above
peers
(-26.1%)
vs Peers
vs Industry
Top tier
Net margin
19.3%
▲
1434%
above
peers
(-1.5%)
vs Peers
vs Industry
Below avg
Gross margin
94.3%
▲
6%
above
peers
(88.9%)
vs Peers
vs Industry
In line
ROA
4.6%
▲
148%
above
peers
(-9.5%)
vs Peers
vs Industry
Top tier
LGND financial health vs Pharmaceuticals peers
D/E ratio
46.9
▲
71%
above
peers
(27.4)
vs Peers
vs Industry
High debt
Current ratio
24.7
▲
609%
above
peers
(3.5)
vs Peers
vs Industry
Strong liquidity
Beta
1.5
▲
157%
above
peers
(0.6)
vs Peers
vs Industry
More volatile
LGND fundamentals radar
LGND
Peer median
Industry
LGND profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
LGND vs peers: key metrics
Latest News
No related news yet